3.230.173.188
dgid:
enl:
npi:0
-Advertisement-
Conference Roundup

Transluminal dilation/goniotomy with Streamline device appears effective through 6 months

Posted on

Transluminal dilation and goniotomy with the Streamline surgical system appears safe and effective in the treatment of eyes with primary open angle glaucoma (POAG) of various severity types through 6 months, according to a study presented at ASCRS 2023.

In a retrospective review of eyes with a POAG diagnosis (mild/moderate: 29; severe: 14; indeterminate: 2) receiving transluminal dilation/goniotomy with Streamline, primary outcomes included changes from baseline in intraocular pressure (IOP) and the number of glaucoma medications at 1-, 3-, and 6-months. The eyes were separated based on phacoemulsification status (standalone Streamline [SL]: 19; combined Streamline and phacoemulsification [SL+IOL]: 26) and compared using Pearson’s chi-squared tests. Secondary outcomes included eyes achieving an IOP ≤ 17 mmHg and ≥ 20% IOP reduction from baseline at 6 months.

At 6 months, IOP was significantly reduced from baseline in both groups. The SL group showed a 40% reduction in IOP, from 26.1 + 5.8 mmHg to 15.7 + 4.0 mmHg (P < 0.01; n = 11), while the SL+IOL group showed a 29% reduction in IOP, from 20.9 + 2.8 mmHg to 14.9 + 2.1 mmHg (P < 0.01; n = 8). The number of glaucoma medications remained unchanged in the SL group and was reduced by one medication in all eyes receiving SL+IOL. An IOP ≤ 17 mmHg was achieved in 73% of SL versus 88% of SL+IOL (P = 0.44), and 91% of SL versus 50% of SL+IOL experienced IOP reduction by ≥ 20% (P = 0.05).

No vision-threatening complications were observed in either group, and no surgical re-interventions were performed.

Reference
Dorairaj SK, et al. 6-Month Outcomes of Transluminal Dilation and Goniotomy with Surgical System. Presented at: ASCRS Annual Meeting 2023.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-